Pictet Asset Management Holding SA Sells 119,719 Shares of Zymeworks Inc. $ZYME

Pictet Asset Management Holding SA lessened its stake in Zymeworks Inc. (NASDAQ:ZYME) by 38.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 188,468 shares of the company’s stock after selling 119,719 shares during the quarter. Pictet Asset Management Holding SA owned about 0.27% of Zymeworks worth $5,121,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Calamos Advisors LLC acquired a new position in Zymeworks during the third quarter worth $1,232,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Zymeworks in the 3rd quarter worth $96,000. ProShare Advisors LLC raised its holdings in shares of Zymeworks by 91.5% during the 3rd quarter. ProShare Advisors LLC now owns 16,390 shares of the company’s stock worth $434,000 after acquiring an additional 7,833 shares during the period. State of Wyoming raised its holdings in shares of Zymeworks by 405.9% during the 3rd quarter. State of Wyoming now owns 14,125 shares of the company’s stock worth $374,000 after acquiring an additional 11,333 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Zymeworks by 11.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 12,947 shares of the company’s stock valued at $352,000 after acquiring an additional 1,325 shares during the last quarter. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Insider Activity

In other news, EVP Adam Schayowitz sold 13,832 shares of the company’s stock in a transaction that occurred on Friday, October 9th. The shares were sold at an average price of $25.85, for a total value of $357,557.20. Following the transaction, the executive vice president directly owned 23,205 shares in the company, valued at approximately $599,849.25. This represents a 37.35% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 37.73% of the company’s stock.

Zymeworks Price Performance

Shares of NASDAQ:ZYME traded down $0.23 during midday trading on Friday, reaching $26.24. 774,980 shares of the company’s stock were exchanged, compared to its average volume of 1,376,009. The stock has a market cap of $1.81 billion, a price-to-earnings ratio of 50.46 and a beta of 1.32. Zymeworks Inc. has a fifty-two week low of $18.20 and a fifty-two week high of $31.97. The firm’s 50 day simple moving average is $27.32 and its two-hundred day simple moving average is $25.48.

Zymeworks (NASDAQ:ZYME) last posted its earnings results on Monday, November 9th. The company reported $2.28 EPS for the quarter, beating analysts’ consensus estimates of $2.27 by $0.01. Zymeworks had a net margin of 16.10% and a return on equity of 22.23%. The company had revenue of $512.92 million for the quarter, compared to analysts’ expectations of $227.40 million. During the same quarter in the prior year, the company posted ($0.26) earnings per share. Zymeworks’s revenue for the quarter was up 828.7% compared to the same quarter last year. Equities research analysts predict that Zymeworks Inc. will post 1.31 earnings per share for the current fiscal year.

Zymeworks News Roundup

These are some of the ZYME news items that stood out recently:

• Positive Sentiment: A report linked Zymeworks’ improved outlook to a milestone payment and a profitable quarter. The company’s latest reported results also beat the cited EPS consensus slightly, while revenue was well above estimates—supportive news, though milestone revenue may not recur. Milestone Payment Lifts Zymeworks Stock Outlook After Profitable Quarter
• Positive Sentiment: Separate reports cited a higher TD Cowen price target, a bullish forecast from Truist, and Zymeworks reaching a new 52-week high after better-than-expected earnings. TD Cowen price target report Truist forecast report New 52-week high report
• Negative Sentiment: HC Wainwright cut its estimates across several upcoming quarters, lowering its FY2026 EPS forecast to $1.19 from $1.51 and moving its FY2027 outlook from $1.32 profit to a projected $0.39 loss. The analyst retained a Buy rating and $56 target, but the revisions signal a less favorable earnings outlook beyond the recent quarter.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on ZYME shares. Deutsche Bank set a $32.00 price objective on shares of Zymeworks in a report on Wednesday, August 26th. Stifel Nicolaus set a $46.00 price target on shares of Zymeworks in a research note on Friday, August 7th. Wolfe Research began coverage on shares of Zymeworks in a report on Thursday, September 17th. They set an “outperform” rating for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zymeworks in a research report on Thursday, October 15th. Finally, Citigroup lifted their price target on shares of Zymeworks from $39.00 to $44.00 and gave the company a “buy” rating in a research report on Wednesday. Twelve investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $43.25.

Zymeworks Company Profile

Zymeworks Inc. is a biotechnology company headquartered in Vancouver, Canada, that develops engineered medicines, with a focus on treatments for cancer and other serious diseases. Its antibody-engineering technologies are designed to create therapies that can engage multiple biological targets or modify immune responses. The company’s lead program is zanidatamab, a HER2-targeted bispecific antibody. In the United States, it is marketed by partner Jazz Pharmaceuticals as Ziihera for certain adults with previously treated, unresectable or metastatic biliary tract cancer.